NGM Biopharmaceuticals Statistics Share Statistics NGM Biopharmaceuticals has 83.46M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 83.46M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 28.89M Failed to Deliver (FTD) Shares 3,367 FTD / Avg. Volume 0.31%
Short Selling Information The latest short interest is 2.39M, so 0% of the outstanding
shares have been sold short.
Short Interest 2.39M Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 1.85
Valuation Ratios The PE ratio is -0.5 and the forward
PE ratio is -3.58.
NGM Biopharmaceuticals's PEG ratio is
0.04.
PE Ratio -0.5 Forward PE -3.58 PS Ratio 16.04 Forward PS 3.6 PB Ratio 0.48 P/FCF Ratio -0.53 PEG Ratio 0.04
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for NGM Biopharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 7.79,
with a Debt / Equity ratio of 0.
Current Ratio 7.79 Quick Ratio 7.79 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $32.01K Profits Per Employee $-1.03M Employee Count 138 Asset Turnover 0.03 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 0% in the
last 52 weeks. The beta is 1.26, so NGM Biopharmaceuticals's
price volatility has been higher than the market average.
Beta 1.26 52-Week Price Change n/a 50-Day Moving Average 1.55 200-Day Moving Average 1.52 Relative Strength Index (RSI) 48.53 Average Volume (20 Days) 1,070,739
Income Statement In the last 12 months, NGM Biopharmaceuticals had revenue of 4.42M
and earned -142.38M
in profits. Earnings per share was -1.73.
Revenue 4.42M Gross Profit 2.2M Operating Income -146.55M Net Income -142.38M EBITDA -144.33M EBIT -146.55M Earnings Per Share (EPS) -1.73
Full Income Statement Balance Sheet The company has 58.81M in cash and 0 in
debt, giving a net cash position of 58.81M.
Cash & Cash Equivalents 58.81M Total Debt n/a Net Cash n/a Retained Earnings -724.01M Total Assets 168.87M Working Capital 136.36M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -132.2M
and capital expenditures -1.25M, giving a free cash flow of -133.45M.
Operating Cash Flow -132.2M Capital Expenditures -1.25M Free Cash Flow -133.45M FCF Per Share -1.62
Full Cash Flow Statement Margins Gross margin is 49.72%, with operating and profit margins of -3317.79% and -3223.34%.
Gross Margin 49.72% Operating Margin -3317.79% Pretax Margin -3223.34% Profit Margin -3223.34% EBITDA Margin -3267.51% EBIT Margin -3317.79% FCF Margin -3021.37%
